Challenges for gene therapy of CNS disorders and implications for Parkinson's disease therapies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson's Disease.Genes · 2021
   Review
2. Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.Viruses · 2014
   Article
3. Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.Human gene therapy · 2014
   Article
4. CSSI workshop in Brazil highlights "Stress Responses in the Nervous System" in relation to neurodegenerative diseases and neuroprotection.Cell stress & chaperones · 2012
   Article

Corrections and comments

• Comment on
  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.2012
• Comment on
  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as